KJIM :: Korean Journal of Internal Medicine

Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy

Anukul Ghimire, Rebecca Brassington, Kim Solez, Aminu Bello

Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer

International Journal of Urology.2024; 31(5): 465. CrossRef

Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment

Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara

Tyrosine Kinase Inhibitor Induced Proteinuria – A Review

Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Yuichi Ando, Hiroyuki Nishiyama, Hideki Shimodaira, Nao Takano, Emiko Sakaida, Koji Matsumoto, Koki Nakanishi, Hideki Sakai, Shokichi Tsukamoto, Keigo Komine, Yoshinari Yasuda, Taigo Kato, Yutaka Fujiwara, Takafumi Koyama, Hiroshi Kitamura, Takashige Kuwa

International Journal of Clinical Oncology.2023; 28(10): 1315. CrossRef

Síndrome nefrótico como manifestación de microangiopatía trombótica secundaria al uso crónico de sunitinib

John Fredy Nieto-Ríos, Camilo Andrés García-Prada, Arbey Aristizabal-Alzate, Gustavo Zuluaga-Valencia, Dahyana Cadavid-Aljure, Lina Maria Serna-Higuita, Luis F. Arias

Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib

Hiroaki Ikesue, Haruna Yamamoto, Masaki Hirabatake, Tohru Hashida, Hobyung Chung, Tetsuro Inokuma, Nobuyuki Muroi

Biological and Pharmaceutical Bulletin.2022; 45(3): 333. CrossRef

Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report

Hsu-Cheng Ko, Huai-Pao Lee, Jiann-Der Wu, Tsung-Liang Ma, Cheng-Huang Shen, Chang-Te Lin, Ming-Chin Cheng, Yeong-Chin Jou

Nephrotic syndrome as a manifestation of thrombotic microangiopathy due to long-term use of sunitinib

John Fredy Nieto-Ríos, Camilo Andrés García-Prada, Arbey Aristizabal-Alzate, Gustavo Zuluaga-Valencia, Dahyana Cadavid-Aljure, Lina Maria Serna-Higuita, Luis F. Arias

Nefrología (English Edition).2022; 42(6): 722. CrossRef

Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib

Kei Saito, Hideki Fujii, Keiji Kono, Ken Hirabayashi, Satoshi Yamatani, Kentaro Watanabe, Shunsuke Goto, Shohei Komatsu, Takumi Fukumoto, Shinichi Nishi

Clinical Kidney Journal.2021; 14(1): 325. CrossRef

Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function

Łukasz Mielczarek, Anna Brodziak, Paweł Sobczuk, Maciej Kawecki, Agnieszka Cudnoch-Jędrzejewska, Anna M. Czarnecka

Cancer Chemotherapy and Pharmacology.2021; 87(6): 723. CrossRef

Identification of VEGF Signaling Inhibition-Induced Glomerular Injury in Rats through Site-Specific Urinary Biomarkers

Yi Yang, Kenneth Kowalkowski, Rita Ciurlionis, Wayne R. Buck, Keith B. Glaser, Daniel H. Albert, Eric A. G. Blomme

International Journal of Molecular Sciences.2021; 22(23): 12629. CrossRef

Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma

Silvia Lai, Maria Ida Amabile, Sandro Mazzaferro, Anna Paola Mitterhofer, Angelo Mazzarella, Alessandro Galani, Giovanni Imbimbo, Rosario Cianci, Marzia Pasquali, Alessio Molfino

Role of rivaroxaban in sunitinib-induced renal injuries via inhibition of oxidative stress-induced apoptosis and inflammation through the tissue nacrosis factor-α induced nuclear factor-κappa B signaling pathway in rats

Naif O. Al-Harbi, Faisal Imam, Mohammad Matar Alharbi, Mohammad Rashid Khan, Wajhul Qamar, Muhammad Afzal, Mohammad Algahtani, Saad Alobaid, Ali Salim Alfardan, Abdulrahman Alshammari, Thamer H. Albekairi, Khalid Saad Alharbi

Journal of Thrombosis and Thrombolysis.2020; 50(2): 361. CrossRef

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors

Haoran Zhang, Xingming Zhang, Xudong Zhu, Yuchao Ni, Jindong Dai, Sha Zhu, Guangxi Sun, Zhipeng Wang, Junru Chen, Jinge Zhao, Hao Zeng, Zi Li, Pengfei Shen

Surveillance de l’hypertension artérielle chez les patients traités par anti-angiogénique par voie orale en pratique quotidienne

Lisa Belaid, Sahar Bayat-Makoei, Brigitte Laguerre, Cécile Vigneau

Néphrologie & Thérapeutique.2018; 14(2): 99. CrossRef

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report

Yassir Sbitti, Adil Debbagh, Khaoula Slimani, Mohamed Mahi, Hassan Errihani, Mohamed Ichou

Journal of Medical Case Reports.2018;[Epub] CrossRef

Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report

Yoshitaka Furuto, Hirotsugu Hashimoto, Akio Namikawa, Haruki Outi, Hiroko Takahashi, Hajime Horiuti, Kazuho Honda, Yuko Shibuya

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Hiroki Ishihara, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Kenji Omae, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Kazunari Tanabe

Japanese Journal of Clinical Oncology.2017; 47(12): 1175. CrossRef

Taichi Hirano, Miyuki Hashimoto, Yu Korogi, Takahiro Tsuji, Kei Miyanaka, Hiroshi Yamasaki, Hiroyuki Tsuda

Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma

Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy, Lajos Géczi

Clinical Genitourinary Cancer.2016; 14(4): 314. CrossRef

Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma

Dong-Hoe Koo, Inkeun Park, Jin-Hee Ahn, Dae-Ho Lee, Dalsan You, In-Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Jae-Lyun Lee

Cancer Chemotherapy and Pharmacology.2016; 77(2): 339. CrossRef

Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma

Hironori Fukuda, Tsunenori Kondo, Shoichi Iida, Toshio Takagi, Kazunari Tanabe

Urologic Oncology: Seminars and Original Investigations.2016; 34(8): 338.e1. CrossRef

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients

Aleksandra Semeniuk-Wojtaś, Arkadiusz Lubas, Rafał Stec, Cezary Szczylik, Stanisław Niemczyk

International Journal of Molecular Sciences.2016; 17(12): 2073. CrossRef

Inhibition of the VEGF signalling pathway and glomerular disorders

Nephrology Dialysis Transplantation.2015; 30(9): 1449. CrossRef

Risks associated with sunitinib use and monitoring to improve patient outcomes

The Korean Journal of Internal Medicine.2014; 29(1): 23. CrossRef

Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis